Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Onco-Innovations Ltd. ( (TSE:ONCO) ) is now available.
Onco-Innovations Limited’s subsidiary, Inka Health, is launching a global consortium named Predicting Oncology Outcomes using Multimodal AI (PROmAI) to advance AI in oncology research. This initiative aims to unite pharmaceutical companies, academic institutions, and data science experts to improve predictive modeling in cancer research, enhancing the accuracy and utility of AI in translational oncology. PROmAI seeks to foster cross-sector collaboration to accelerate personalized cancer care and establish standards for AI transparency and trustworthiness, marking a strategic milestone for Inka Health in the field of AI-driven oncology solutions.
More about Onco-Innovations Ltd.
Onco-Innovations Limited is a Canadian-based company focused on cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company holds an exclusive worldwide license to patented technology targeting solid tumors. Its subsidiary, Inka Health, is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI, with its proprietary platform SynoGraph enhancing precision medicine.
Average Trading Volume: 110,408
Learn more about ONCO stock on TipRanks’ Stock Analysis page.